Cargando…

Analysis of the expression and genetic alteration of CLDN18 in gastric cancer

Claudin 18 (CLDN18) is a transmembrane protein that localizes to apical regions to form tight junction complexes. Abnormal expression of CLDN18 has been reported in gastric cancer (GC). The expression, genetic alterations, and prognostic role of CLDN18 were analyzed using public data from The Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jian, Zhang, Yao, Hu, Dengmin, Gong, Tuping, Xu, Run, Gao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425459/ https://www.ncbi.nlm.nih.gov/pubmed/32668412 http://dx.doi.org/10.18632/aging.103457

Ejemplares similares

Prehospital delay and its associated psychosocial factors in patients presenting with acute appendicitis in a southwestern city in China: a single-centre prospective observational study
por: Li, Jian, et al.
Publicado: (2019)

The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Wei-Han, et al.
Publicado: (2020)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
por: Nakayama, Izuma, et al.
Publicado: (2019)

Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis
por: Gao, Fangmei, et al.
Publicado: (2019)

CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis
por: Han, Lu, et al.
Publicado: (2023)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
por: Shu, Yang, et al.
Publicado: (2018)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis
por: Zhang, Wei-na, et al.
Publicado: (2016)

Membranous and nuclear staining of CLDN18 in HPV‐independent and HPV‐associated endocervical adenocarcinomas
por: Du, Xiuzhen, et al.
Publicado: (2022)

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

CLDN10 is Associated with Papillary Thyroid Cancer Progression
por: Zhou, Yili, et al.
Publicado: (2018)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival
por: Eftang, Lars L, et al.
Publicado: (2013)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

CLDN3 expression and function in pregnancy-induced hypertension
por: Zhao, Aixin, et al.
Publicado: (2020)

Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer
por: Rao, XiongHui, et al.
Publicado: (2021)

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
por: Kwon, Mi Jeong, et al.
Publicado: (2010)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Genetic and molecular analysis of the CLDN14 gene in Moroccan family with non-syndromic hearing loss
por: Charif, Majida, et al.
Publicado: (2013)

CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer
por: Yu, Site, et al.
Publicado: (2019)

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
por: Konno, Hiroyasu, et al.
Publicado: (2022)

Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis
por: Whitcomb, David C., et al.
Publicado: (2012)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2014)

miR-767-3p Inhibits Growth and Migration of Lung Adenocarcinoma Cells by Regulating CLDN18
por: Wan, Yi Long, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_39o2piee38nssgp6qso7jp4ag0